ADXS vs. CANF, EFTR, TENX, GRAY, CVKD, TRVN, CMMB, SHPH, IBIO, and UPC
Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Tenax Therapeutics (TENX), Graybug Vision (GRAY), Cadrenal Therapeutics (CVKD), Trevena (TRVN), Chemomab Therapeutics (CMMB), Shuttle Pharmaceuticals (SHPH), iBio (IBIO), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.
Ayala Pharmaceuticals (NASDAQ:ADXS) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.
Can-Fite BioPharma received 1 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 2.50% of users gave Can-Fite BioPharma an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
Ayala Pharmaceuticals has a net margin of 0.00% compared to Can-Fite BioPharma's net margin of -1,027.46%. Can-Fite BioPharma's return on equity of -113.75% beat Ayala Pharmaceuticals' return on equity.
7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Can-Fite BioPharma has higher revenue and earnings than Ayala Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ayala Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.
Can-Fite BioPharma has a consensus price target of $15.00, indicating a potential upside of 657.58%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than Ayala Pharmaceuticals.
In the previous week, Can-Fite BioPharma had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.
Summary
Can-Fite BioPharma beats Ayala Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Ayala Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ayala Pharmaceuticals Competitors List
Related Companies and Tools
